The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinoma

Medical Oncology and Translational Research, Institut de Cancérologie Gustave Roussy,Villejuif, France.
Annals of Oncology (Impact Factor: 7.04). 04/2009; 20(7):1257-63. DOI: 10.1093/annonc/mdn785
Source: PubMed


The expression levels of excision repair cross-complementation group 1 (ERCC1), replication protein A (RPA) and xeroderma pigmentosum group F (XPF) nucleotide excision repair proteins may be important in the response to platin-based therapy in lung cancer patients. It is not known whether ERCC1, RPA and XPF expression levels differ between ever smokers (ES) and never smokers (NS).
ERCC1, RPA and XPF expression levels were immunohistochemically evaluated in 125 patients with resected lung adenocarcinoma (AC) and carefully reviewed smoking status.
ERCC1 was correlated with XPF (P = 0.001), but not with RPA (P = 0.11). In the univariate analysis, ERCC1 and XPF levels were higher in NS compared with ES (P = 0.004 and P = 0.003, respectively). In the multivariate analysis, the smoking status was predictive of the ERCC1 level [odds ratio (OR) 2.5, 95% confidence interval (CI) 1.03-6.2] after adjustment for variables linked to the smoking status, including age and the presence of bronchioloalveolar (BAC) features. The smoking status was also predictive of both RPA (OR 6.7, 95% CI 1.5-33.3) and XPF levels (OR 12.5, 95% CI 2.9-50) after adjusting for age, sex and BAC features.
In patients with resected lung AC, ERCC1, RPA and XPF expression levels are higher in NS compared with ES.

Full-text preview

Available from:
  • Source
    • "It is well known that cancer progression is associated with persistent high-risk human papillomaviruses (HPV) infection and with deregulated viral gene expression, which leads to excessive cell proliferation, deficient DNA repair, and the accumulation of genetic damage in the infected cell[2]. Dozens of genes are involved in DNA damage repair to maintain genomic stability through different pathways, including direct repair, base excision repair, nucleotide cisplatine resistance and clinical course of human cancers, including squamous cell carcinoma of the head and neck (SCCHN)10111213141516. Additionally, it is also hypothesized that XPF has potential to guide next-generation personalized cancer therapy since expression level of XPF in squamous cell carcinoma of the head and neck (SCCHN) tumors correlates with clinical response to DNA damaging agents[10]. "

    Full-text · Article · Apr 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: The main problem for vector quantisation is the codebook generation. The LBG method solves it with an iterative approach. This algorithm needs a long training sequence and an initial approximation of the codebook. These problems may be overcome by using space filling curves, also called Peano's curves, which are mappings from the unitary interval (image point) to the unitary hypercube. By using this kind of mapping the generation of the codebook, is reduced to the computation of the one-dimensional (optimum) quantiser associated to the probability density function (pdf) of the image points on the Hilbert curve. The paper describes the way of applying these mappings: a new algorithm is derived, generating codebooks for vector quantisation, and experimental results on image coding are provided.
    No preview · Conference Paper · May 1986
  • [Show abstract] [Hide abstract]
    ABSTRACT: ERCC1 plays a critical role in the repair of lesions in DNA induced by cisplatin. It has been demonstrated that, in patients with resected NSCLC, those with ERCC1-negative tumours had greater benefit from adjuvant chemotherapy than patients with ERCC1-positive tumours. On the other hand, patients with ERCC1-positive tumours have a better prognosis. ERCC1 can be evaluated either by the level of protein expression on immunohistochemical analysis or by quantification of its mRNA expression. At present ERCC1 appears to be a promising biomarker for predicting the benefit of cisplatin based chemotherapy and its modulation could allow sensitisation of tumour cells to this drug. Its use in daily clinical practice requires a further stage of prospective validation studies which are already in progress in patients both with completely resected NSCL or metastatic disease.
    No preview · Article · Apr 2010 · Revue des Maladies Respiratoires
Show more